Why Did Buffett Sell the S&P 500?
Warren Buffett has always been an advocate of investing in…
Sell
9
CANC Quote, Financials, Valuation and Earnings
Last price:
$24.51
Seasonality move
:
1.39%
Day range:
$24.43 - $24.78
52-week range:
$23.97 - $30.11
Dividend yield:
2.04%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
6.3K
Avg. volume:
7.4K
1-year change:
-12.78%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CANC
Tema Oncology ETF
|
-- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- |
|
EDOC
Global X Telemedicine & Digital Health ETF
|
-- | -- | -- | -- | -- |
|
FMED
Fidelity Disruptive Medicine ETF
|
-- | -- | -- | -- | -- |
|
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
|
-- | -- | -- | -- | -- |
|
MEDX
Horizon Kinetics Medical ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CANC
Tema Oncology ETF
|
$24.53 | -- | -- | -- | $0.73 | 2.04% | -- |
|
AGNG
Global X Aging Population ETF
|
$31.25 | -- | -- | -- | $0.15 | 0.8% | -- |
|
EDOC
Global X Telemedicine & Digital Health ETF
|
$9.38 | -- | -- | -- | $0.00 | 0% | -- |
|
FMED
Fidelity Disruptive Medicine ETF
|
$23.89 | -- | -- | -- | $0.11 | 0.47% | -- |
|
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
|
$29.47 | -- | -- | -- | $0.47 | 0.49% | -- |
|
MEDX
Horizon Kinetics Medical ETF
|
$27.64 | -- | -- | -- | $0.51 | 1.65% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CANC
Tema Oncology ETF
|
-- | 1.116 | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | 0.954 | -- | -- |
|
EDOC
Global X Telemedicine & Digital Health ETF
|
-- | 1.921 | -- | -- |
|
FMED
Fidelity Disruptive Medicine ETF
|
-- | 1.199 | -- | -- |
|
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
|
-- | 1.300 | -- | -- |
|
MEDX
Horizon Kinetics Medical ETF
|
-- | 0.877 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CANC
Tema Oncology ETF
|
-- | -- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- | -- |
|
EDOC
Global X Telemedicine & Digital Health ETF
|
-- | -- | -- | -- | -- | -- |
|
FMED
Fidelity Disruptive Medicine ETF
|
-- | -- | -- | -- | -- | -- |
|
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
|
-- | -- | -- | -- | -- | -- |
|
MEDX
Horizon Kinetics Medical ETF
|
-- | -- | -- | -- | -- | -- |
Tema Oncology ETF vs. Competitors
-
Which has Higher Returns CANC or AGNG?
Global X Aging Population ETF has a net margin of -- compared to Tema Oncology ETF's net margin of --. Tema Oncology ETF's return on equity of -- beat Global X Aging Population ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CANCTema Oncology ETF-- -- -- AGNGGlobal X Aging Population ETF-- -- -- -
What do Analysts Say About CANC or AGNG?
Tema Oncology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Aging Population ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema Oncology ETF has higher upside potential than Global X Aging Population ETF, analysts believe Tema Oncology ETF is more attractive than Global X Aging Population ETF.
Company Buy Ratings Hold Ratings Sell Ratings CANCTema Oncology ETF0 0 0 AGNGGlobal X Aging Population ETF0 0 0 -
Is CANC or AGNG More Risky?
Tema Oncology ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Global X Aging Population ETF has a beta of 0.797, suggesting its less volatile than the S&P 500 by 20.348%.
-
Which is a Better Dividend Stock CANC or AGNG?
Tema Oncology ETF has a quarterly dividend of $0.73 per share corresponding to a yield of 2.04%. Global X Aging Population ETF offers a yield of 0.8% to investors and pays a quarterly dividend of $0.15 per share. Tema Oncology ETF pays -- of its earnings as a dividend. Global X Aging Population ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CANC or AGNG?
Tema Oncology ETF quarterly revenues are --, which are smaller than Global X Aging Population ETF quarterly revenues of --. Tema Oncology ETF's net income of -- is lower than Global X Aging Population ETF's net income of --. Notably, Tema Oncology ETF's price-to-earnings ratio is -- while Global X Aging Population ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema Oncology ETF is -- versus -- for Global X Aging Population ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CANCTema Oncology ETF-- -- -- -- AGNGGlobal X Aging Population ETF-- -- -- --
-
Which has Higher Returns CANC or EDOC?
Global X Telemedicine & Digital Health ETF has a net margin of -- compared to Tema Oncology ETF's net margin of --. Tema Oncology ETF's return on equity of -- beat Global X Telemedicine & Digital Health ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CANCTema Oncology ETF-- -- -- EDOCGlobal X Telemedicine & Digital Health ETF-- -- -- -
What do Analysts Say About CANC or EDOC?
Tema Oncology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Telemedicine & Digital Health ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema Oncology ETF has higher upside potential than Global X Telemedicine & Digital Health ETF, analysts believe Tema Oncology ETF is more attractive than Global X Telemedicine & Digital Health ETF.
Company Buy Ratings Hold Ratings Sell Ratings CANCTema Oncology ETF0 0 0 EDOCGlobal X Telemedicine & Digital Health ETF0 0 0 -
Is CANC or EDOC More Risky?
Tema Oncology ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Global X Telemedicine & Digital Health ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CANC or EDOC?
Tema Oncology ETF has a quarterly dividend of $0.73 per share corresponding to a yield of 2.04%. Global X Telemedicine & Digital Health ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tema Oncology ETF pays -- of its earnings as a dividend. Global X Telemedicine & Digital Health ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CANC or EDOC?
Tema Oncology ETF quarterly revenues are --, which are smaller than Global X Telemedicine & Digital Health ETF quarterly revenues of --. Tema Oncology ETF's net income of -- is lower than Global X Telemedicine & Digital Health ETF's net income of --. Notably, Tema Oncology ETF's price-to-earnings ratio is -- while Global X Telemedicine & Digital Health ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema Oncology ETF is -- versus -- for Global X Telemedicine & Digital Health ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CANCTema Oncology ETF-- -- -- -- EDOCGlobal X Telemedicine & Digital Health ETF-- -- -- --
-
Which has Higher Returns CANC or FMED?
Fidelity Disruptive Medicine ETF has a net margin of -- compared to Tema Oncology ETF's net margin of --. Tema Oncology ETF's return on equity of -- beat Fidelity Disruptive Medicine ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CANCTema Oncology ETF-- -- -- FMEDFidelity Disruptive Medicine ETF-- -- -- -
What do Analysts Say About CANC or FMED?
Tema Oncology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Fidelity Disruptive Medicine ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema Oncology ETF has higher upside potential than Fidelity Disruptive Medicine ETF, analysts believe Tema Oncology ETF is more attractive than Fidelity Disruptive Medicine ETF.
Company Buy Ratings Hold Ratings Sell Ratings CANCTema Oncology ETF0 0 0 FMEDFidelity Disruptive Medicine ETF0 0 0 -
Is CANC or FMED More Risky?
Tema Oncology ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Fidelity Disruptive Medicine ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CANC or FMED?
Tema Oncology ETF has a quarterly dividend of $0.73 per share corresponding to a yield of 2.04%. Fidelity Disruptive Medicine ETF offers a yield of 0.47% to investors and pays a quarterly dividend of $0.11 per share. Tema Oncology ETF pays -- of its earnings as a dividend. Fidelity Disruptive Medicine ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CANC or FMED?
Tema Oncology ETF quarterly revenues are --, which are smaller than Fidelity Disruptive Medicine ETF quarterly revenues of --. Tema Oncology ETF's net income of -- is lower than Fidelity Disruptive Medicine ETF's net income of --. Notably, Tema Oncology ETF's price-to-earnings ratio is -- while Fidelity Disruptive Medicine ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema Oncology ETF is -- versus -- for Fidelity Disruptive Medicine ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CANCTema Oncology ETF-- -- -- -- FMEDFidelity Disruptive Medicine ETF-- -- -- --
-
Which has Higher Returns CANC or HRTS?
Tema GLP-1, Obesity & Cardiometabolic ETF has a net margin of -- compared to Tema Oncology ETF's net margin of --. Tema Oncology ETF's return on equity of -- beat Tema GLP-1, Obesity & Cardiometabolic ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CANCTema Oncology ETF-- -- -- HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- -
What do Analysts Say About CANC or HRTS?
Tema Oncology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Tema GLP-1, Obesity & Cardiometabolic ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema Oncology ETF has higher upside potential than Tema GLP-1, Obesity & Cardiometabolic ETF, analysts believe Tema Oncology ETF is more attractive than Tema GLP-1, Obesity & Cardiometabolic ETF.
Company Buy Ratings Hold Ratings Sell Ratings CANCTema Oncology ETF0 0 0 HRTSTema GLP-1, Obesity & Cardiometabolic ETF0 0 0 -
Is CANC or HRTS More Risky?
Tema Oncology ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Tema GLP-1, Obesity & Cardiometabolic ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CANC or HRTS?
Tema Oncology ETF has a quarterly dividend of $0.73 per share corresponding to a yield of 2.04%. Tema GLP-1, Obesity & Cardiometabolic ETF offers a yield of 0.49% to investors and pays a quarterly dividend of $0.47 per share. Tema Oncology ETF pays -- of its earnings as a dividend. Tema GLP-1, Obesity & Cardiometabolic ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CANC or HRTS?
Tema Oncology ETF quarterly revenues are --, which are smaller than Tema GLP-1, Obesity & Cardiometabolic ETF quarterly revenues of --. Tema Oncology ETF's net income of -- is lower than Tema GLP-1, Obesity & Cardiometabolic ETF's net income of --. Notably, Tema Oncology ETF's price-to-earnings ratio is -- while Tema GLP-1, Obesity & Cardiometabolic ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema Oncology ETF is -- versus -- for Tema GLP-1, Obesity & Cardiometabolic ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CANCTema Oncology ETF-- -- -- -- HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- --
-
Which has Higher Returns CANC or MEDX?
Horizon Kinetics Medical ETF has a net margin of -- compared to Tema Oncology ETF's net margin of --. Tema Oncology ETF's return on equity of -- beat Horizon Kinetics Medical ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CANCTema Oncology ETF-- -- -- MEDXHorizon Kinetics Medical ETF-- -- -- -
What do Analysts Say About CANC or MEDX?
Tema Oncology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Horizon Kinetics Medical ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema Oncology ETF has higher upside potential than Horizon Kinetics Medical ETF, analysts believe Tema Oncology ETF is more attractive than Horizon Kinetics Medical ETF.
Company Buy Ratings Hold Ratings Sell Ratings CANCTema Oncology ETF0 0 0 MEDXHorizon Kinetics Medical ETF0 0 0 -
Is CANC or MEDX More Risky?
Tema Oncology ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Horizon Kinetics Medical ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CANC or MEDX?
Tema Oncology ETF has a quarterly dividend of $0.73 per share corresponding to a yield of 2.04%. Horizon Kinetics Medical ETF offers a yield of 1.65% to investors and pays a quarterly dividend of $0.51 per share. Tema Oncology ETF pays -- of its earnings as a dividend. Horizon Kinetics Medical ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CANC or MEDX?
Tema Oncology ETF quarterly revenues are --, which are smaller than Horizon Kinetics Medical ETF quarterly revenues of --. Tema Oncology ETF's net income of -- is lower than Horizon Kinetics Medical ETF's net income of --. Notably, Tema Oncology ETF's price-to-earnings ratio is -- while Horizon Kinetics Medical ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema Oncology ETF is -- versus -- for Horizon Kinetics Medical ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CANCTema Oncology ETF-- -- -- -- MEDXHorizon Kinetics Medical ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will SoundHound AI Stock Recover?
SoundHound AI (NASDAQ:SOUN) is a leading maker of artificial intelligence…
What Stocks Did Warren Buffett Just Buy?
In Q4 of last year, Warren Buffett added to or…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
78
AJINY alert for Mar 29
Ajinomoto [AJINY] is up 99.61% over the past day.
Buy
69
AGX alert for Mar 29
Argan [AGX] is up 19.83% over the past day.
Sell
24
AIR alert for Mar 29
AAR [AIR] is down 16.36% over the past day.
